Using Rivaroxaban to Prevent Thrombus After Heart Attack

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and effectiveness of using a Century Clot-guided low-dose rivaroxaban in combination with standard dual antiplatelet therapy (DAPT) to prevent left ventricular thrombus (LVT) formation in patients who have experienced an anterior ST-segment elevation myocardial infarction (STEMI) and undergone primary percutaneous coronary intervention (PCI). Eligible patients will receive standard DAPT and will be randomly assigned to receive either the additional rivaroxaban or continue with DAPT alone. The study aims to evaluate the incidence of LVT and other adverse clinical events at one month and twelve months post-STEMI. The goal is to optimize antithrombotic therapy while minimizing bleeding risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ischemic chest discomfort for at least 30 minutes, with at least 1-mm (0.1-mv) ST-segment elevation in anterior leads on a standard 12-lead electrocardiogram.
* Patients provide written informed consent prior to enrollment.

Exclusion Criteria:

* Intracranial, gastrointestinal, or urogenital bleeding within 6 months
* Requiring OAC therapy (eg, atrial fibrillation, deep vein thrombosis, pulmonary thromboembolism);
* Bleeding diathesis, thrombocytopenia (platelet \<100,000/mL) or hemoglobin \<10 g/dL, and CRUSADE score-based high bleeding risk
* Hepatic dysfunction (serum liver enzyme\>3 times the normal limit)
* Renal failure (eGFR \<15 ml/min/1.73m2 or requiring dialysis)
* Severe chronic obstructive pulmonary disease
* Severe bradycardia (sick sinus syndrome or high degree atrioventricular block without pacemaker protection)
* Drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin
* Life expectancy \< 1 year

Where it's running

• Affiliated Hospital of Zunyi Medical University
  Zunyi, Guizhou, China Recruiting

Study contacts

• Principal investigator: Cai De Jin, MD — Zunyi Medical College
• Study coordinator: Cai De Jin, MD
• Email: jincaide@zmu.edu.cn
• Phone: 86+178-0250-2582

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Noninvasive Venous Stasis to Help Reperfuse the Heart in STEMI

  This study tests whether briefly restricting venous return with a cuff before the usual heart attack treatment helps restore blood flow on its own.

  Recruiting at 2 sites Firat University · Elâzığ, Elaziğ and 1 other locations · NCT07689591

• Sustained thrombectomy plus PCI versus PCI alone in high thrombus burden STEMI

  This trial tests whether adding sustained mechanical thrombectomy to PCI helps patients with STEMI and large clot burden, compared to PCI alone.

  Recruiting Phase 2/3 Oxford University Hospitals NHS Trust · Oxford, Oxfordshire · NCT07687576

• Antithrombotic options for acute coronary syndrome with coronary artery ectasia

  This trial tests whether using rivaroxaban instead of the usual aspirin plus clopidogrel better prevents clot-related complications in adults hospitalized with acute coronary syndrome who have coronary artery ectasia.

  Recruiting Phase 4 Instituto Nacional de Cardiologia Ignacio Chavez · Mexico City, Tlalpan · NCT07511257

• Prehospital pulse-dose methylprednisolone for ST-elevation myocardial infarction

  We will test if a single high dose of methylprednisolone given before hospital arrival can reduce heart muscle damage in adults having an ST-elevation heart attack.

  Recruiting Phase 3 Copenhagen University Hospital, Rigshospitalet · Aalborg and 3 other locations · NCT07478003

• Epicardial fat CT in patients after heart attack

  This trial will test whether dapagliflozin or semaglutide reduces epicardial (around-the-heart) fat over 12 months in adults hospitalized with ST-elevation or non‑ST‑elevation myocardial infarction.

  Recruiting Phase 3 Instituto Mexicano del Seguro Social · León, Guanajuato · NCT07297589

• AI-guided early thrombolysis for people with STEMI

  This trial tests whether an AI-assisted mobile app can help clinicians give earlier thrombolysis (plus planned PCI) for adults with STEMI who are unlikely to have the lesion opened within 120 minutes.

  Recruiting Shenyang Northern Hospital · Shenyang, Liaoning · NCT07160491

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.